Outpatient Use of Low Molecular Weight Heparin Monotherapy for First-Line Treatment of Venous Thromboembolism in Advanced Cancer

Oncologist - United States
doi 10.1634/theoncologist.2011-0323
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Rivaroxaban Versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer

In Vivo
BiochemistryMedicineGeneticsPharmacologyMolecular Biology
2020English

Low Molecular-Weight Heparin Is Better Than Warfarin for Prevention of Recurrent Venous Thromboembolism in Cancer Patients

Clinical Research in Practice: The Journal of Team Hippocrates
2017English

Economic Analysis of Low-Dose Heparin vs the Low-Molecular-Weight Heparin Enoxaparin for Prevention of Venous Thromboembolism After Colorectal Surgery

Archives of Internal Medicine
1999English

Cost-Effectiveness Analysis of Treatment of Venous Thromboembolism With Rivaroxaban Compared With Combined Low Molecular Weight Heparin/Vitamin K Antagonist

Thrombosis Journal
Hematology
2015English

Use of Low-Molecular-Weight Heparin in the Treatment of Venous Thromboembolic Disease: Answers to Frequently Asked Questions

Mayo Clinic Proceedings
Medicine
1998English

Treatment of Lived Vasculopathy With Low-Molecular-Weight Heparin

Archives of Dermatology
2003English

Low Molecular Weight Heparin

Reactions Weekly
2014English

Low Molecular Weight Heparin

Journal of Cardiothoracic and Vascular Anesthesia
Cardiovascular MedicineAnesthesiologyPain MedicineCardiology
1992English

Low Molecular Weight Heparin

Reactions Weekly
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy